🇺🇸 FDA
Patent

US 10533227

Compositions, kits, and methods for identification, assessment, prevention and therapy of breast and ovarian cancer

granted A61PA61P35/00

Quick answer

US patent 10533227 (Compositions, kits, and methods for identification, assessment, prevention and therapy of breast and ovarian cancer) held by The Board of Regents of the University of Texas System expires Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Jan 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61P, A61P35/00